Vanda Pharmaceuticals (VNDA) Applications for HETLIOZ Accepted by FDA for Priority Review

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to Vanda Pharmaceuticals (VNDA) Applications for HETLIOZ Accepted by FDA for Priority Review

Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 12c

August 5, 2020 4:03 PM EDT

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.16, $0.12 better than the analyst estimate of $0.04. Revenue for the quarter came in at $62.21 million versus the consensus estimate of $61.95 million.

Key Financial and Corporate Highlights

Total revenues from HETLIOZ® and Fanapt® were $62.2 million in the second quarter of... More